Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?
D. Fuhrmann
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorA. Lippold
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorF. Borrosch
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorU. Ellwanger
Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft, D-72076 Tübingen, Germany
Search for more papers by this authorC. Garbe
Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft, D-72076 Tübingen, Germany
Universitätshautklinik, D-72076 Tübingen, Germany
Search for more papers by this authorL. Suter
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorD. Fuhrmann
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorA. Lippold
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorF. Borrosch
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorU. Ellwanger
Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft, D-72076 Tübingen, Germany
Search for more papers by this authorC. Garbe
Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft, D-72076 Tübingen, Germany
Universitätshautklinik, D-72076 Tübingen, Germany
Search for more papers by this authorL. Suter
Fachklinik Hornheide, Dorbaumstraße 300, D-48157 Münster, Germany
Search for more papers by this authorAbstract
Background Several authors have recommended adjuvant radiotherapy following resection of regional lymph node metastases in cutaneous malignant melanoma. There is, however, little evidence from controlled trials that patients benefit from this treatment.
Objectives To evaluate the usefulness of adjuvant radiotherapy following resection of lymph node metastases in cutaneous malignant melanoma.
Methods We performed a retrospective study comparing 58 patients who underwent radiotherapy following resection of regional lymph node metastases with 58 controls from another centre who exclusively underwent regional lymphadenectomy. Patients and their controls were matched with respect to the number of tumour-bearing lymph nodes (1 vs. > 1) and to gender, although the proportion of thick tumours was greater in the irradiation group.
Results The overall survival curves were almost identical in the two groups. There were nine disease recurrences in the study group and 12 in the control group (not significant). Regional recurrences in the irradiated patients were usually accompanied by metastases at other sites.
Conclusions The present study does not support the recommendation of adjuvant radiotherapy following resection of regional lymph node metastases in patients with malignant melanoma.
References
- 1 Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16 (Suppl. 1): 34 – 44.
- 2
Creagan ET,
Cupps RE &
Ivins JC et al.
Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. A randomized, prospective study.
Cancer
1978; 42: 2206
–
10.
10.1002/1097-0142(197811)42:5<2206::AID-CNCR2820420518>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 3 Jonk A, Kroon BB & Rumke P et al. Results of radical dissection of the groin in patients with stage II melanoma and histologically proven metastases of the iliac or obturator lymph nodes, or both. Surg Gynecol Obstet 1988; 167: 28 – 32.
- 4 Ang KK, Peters LJ & Weber RS et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30: 795 – 8.
- 5
Peschel RE.
Radiobiology and radiation treatment of malignant melanoma: a review.
Radiat Oncol Invest
1994; 1: 249
–
60.
10.1002/roi.2970010502 Google Scholar
- 6 Burmeister BH, Smithers BM & Poulsen MG et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369 – 71.
- 7
Burmeister BH,
Poulsen MG &
Smithers BM et al.
Radiation therapy following nodal dissection for malignant melanoma: report on a phase II study.
Melanoma Res
1997; 7 (Suppl. 1): S18
–
19.
10.1097/00008390-199706001-00063 Google Scholar
- 8 Strom EA & Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995; 2: 445 – 9.
- 9 O’Brien CJ, Gianoutsos MP & Morgan MJ. Neck dissection for cutaneous malignant melanoma. World J Surg 1992; 16: 222 – 6.
- 10 O’Brien CJ, Petersen-Schaefer K & Ruark D et al. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck 1995; 17: 232 – 41.
- 11
O’Brien CJ,
Petersen-Schaefer K &
Stevens GN et al.
Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.
Head Neck
1997; 19: 589
–
94.DOI: 10.1002/(sici)1097-0347(199710)19:7<589::aid-hed5>3.0.co;2-3
10.1002/(sici)1097-0347(199710)19:7<589::aid-hed5>3.0.co;2-3 CAS PubMed Web of Science® Google Scholar
- 12 Malata CM, Camilleri IG & McLean NR et al. Metastatic tumours of the parotid gland. Br J Oral Maxillofac Surg 1998; 36: 190 – 5.
- 13 Malata CM, Camilleri IG & McLean NR et al. Malignant tumours of the parotid gland: a 12-year review. Br J Plast Surg 1997; 50: 600 – 8.
- 14 Krähn G, Schmidt M & Busch M et al. Strahlentherapie von Lymphknotenmetastasen des malignen Melanoms: Ergebnisse einer retrospektiven Studie. In: Strahlentherapie Dermatologischer Erkrankungen( RU Peter, G Plewig, eds). Vienna: Blackwell Wissenschaft, 1996: 111 – 19.
- 15 Corry J, Smith JG & Bishop M et al. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999; 44: 1065 – 9.DOI: 10.1016/s0360-3016(99)00131-5
- 16 Sobin LH & Wittekind C. UICC TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley and Sons, Inc., 1997.
- 17 Ehring F, Hellenthal W & Schumann J. Das Cobaltron II, ein neues 60Co-Kurzdistanz-Therapiegerät. Strahlentherapie 1968; 135: 417 – 21.
- 18 Fuhrmann D, Borrosch F & Lippold A et al. Strahlentherapie nach Excision regionärer Lymphknotenmetastasen maligner Melanome. Zbl Haut 1996; 167: 591.
- 19 Green SB & Byar DP. Using observational data from registries to compare treatments: the fallacy of omnimetrics. Stat Med 1984; 3: 361 – 70.
- 20 Pinsky CM. Experience with historical control studies in cancer immunotherapy. Stat Med 1984; 3: 325 – 9.
- 21 Green SB. Patient heterogeneity and the need for randomized clinical trials. Controlled Clin Trials 1982; 3: 189 – 98.
- 22 Byar DP, Simon RM & Friedewald WT et al. Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 1976; 295: 74 – 80.
- 23 Bevilacqua RG, Coit DG & Rogatko A et al. Axillary dissection in melanoma. Prognostic variables in node positive patients. Ann Surg 1990; 212: 125 – 31.
- 24 Belli F, Nava M & Santinami M et al. Management of nodal metastases from head and neck melanoma. J Surg Oncol 1989; 42: 47 – 53.
- 25
Drepper H,
Biess B &
Hofherr B et al.
The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide.
Cancer
1993; 71: 1239
–
46.
10.1002/1097-0142(19930215)71:4<1239::AID-CNCR2820710412>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 26 Buzaid AC, Tinoco LA & Jendiroba D et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995; 13: 2361 – 8.
- 27 Buzzell RA & Zitelli JA. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 1996; 34: 798 – 803.
- 28 Parker T & Zitteli JA. Malignant melanoma. Dermatol Surg 1996; 22: 234 – 40.
- 29 Callery C, Cochran AJ & Roe DJ et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982; 196: 69 – 75.
- 30 Lee RJ, Gibbs JF & Proulx GM et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46: 467 – 74.DOI: 10.1016/s0360-3016(99)00431-9
- 31 Tillman DM, Aitchison T & Watt DC et al. Stage II melanoma in the west of Scotland. 1976–85: prognostic factors for survival. Eur J Cancer 1991; 27: 870 – 6.
- 32 Orfanos CE, Jung EG & Rassner G et al. Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Stand 1993/94. Hautarzt 1994; 45: 285 – 91.DOI: 10.1007/s001050050071
